首页> 美国卫生研究院文献>Prostate International >Status of TMPRSS2–ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism
【2h】

Status of TMPRSS2–ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism

机译:印度前列腺癌患者中TMPRSS2-ERG融合的现状:与临床病理细节和TMPRSS2 Met160Val多态性的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundProstate cancer (PCa) shows considerable clinical heterogeneity that has been primarily attributed to variable molecular alterations. TMPRSS2–ERG fusion is one such molecular subtype that has been associated with predominantly poor prognosis. More recently, a single nucleotide polymorphism (SNP) in the TMPRSS2 gene rs12329760 C>T (Met160Val) has been shown to positively correlate with the fusion status and also to be associated with increased risk for PCa. The aim of the present study is to determine the frequency of TMPRSS2–ERG fusion and association of rs12329760 in Indian PCa patients with fusion status.
机译:背景前列腺癌(PCa)表现出相当大的临床异质性,这主要归因于可变的分子变化。 TMPRSS2-ERG融合是这样一种分子亚型,主要与不良预后有关。最近,TMPRSS2基因rs12329760 C> T(Met160Val)中的单核苷酸多态性(SNP)已显示与融合状态呈正相关,并且也与PCa风险增加相关。本研究的目的是确定印度PCa融合状态患者中TMPRSS2-ERG融合的频率和rs12329760的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号